Benefits
Amino acid and protein absorption enhancement
A 2026 double-blind RCT in 30 healthy adults published in Nutrients confirmed AstraGin® significantly improved the absorption of key amino acids from whey protein — with improved muscle strength and mass after 4 weeks of resistance training. AstraGin® increases the expression of PEPT1 (peptide transporter) and amino acid transporter proteins in intestinal epithelium, enabling greater amino acid uptake per gram of dietary protein consumed.
Multi-nutrient bioavailability improvement
Over 20 studies confirm AstraGin® increases the absorption of a broad range of nutrients including L-citrulline, creatine, folate, glucosamine, curcumin, vitamins B1/B9/B12/C/D, and omega-3 fatty acids. This broad-spectrum absorption enhancement makes AstraGin® one of the most versatile co-ingredients in supplement formulation — improving the efficacy of virtually any formula it is included in.
Gut health and microbiome support
A human clinical trial in participants with gut health concerns demonstrated AstraGin® (100 mg/day, 3 months) significantly improved intestinal barrier integrity, increased beneficial bacteria populations (420% increase in Faecalibacterium prausnitzii, 180% increase in Bifidobacterium adolescentis), and reduced harmful bacteria — positioning AstraGin® as both an absorption enhancer and a gut health ingredient.
Mechanism of action
Intestinal transporter upregulation and tight junction support
AstraGin® astragaloside IV and ginsenoside Rb1 upregulate the expression of intestinal nutrient transporter proteins (SGLT1, PEPT1, CAT1) through NF-κB modulation and mTOR-mediated protein synthesis — increasing the transport capacity of intestinal epithelial cells for amino acids, glucose, and other nutrients. Simultaneously, AstraGin® strengthens tight junction proteins (ZO-1, occludin) reducing intestinal permeability and improving the selective barrier function that underlies both nutrient absorption efficiency and immune defense.
Clinical trials
Randomized, double-blind, placebo-controlled crossover trial (NCT06110260) of AstraGin® (50 mg, standardized Astragalus membranaceus and Panax notoginseng saponins extract) on whey protein amino acid absorption in 30 healthy adults across three age groups (18-25, 26-59, 60-80 years). Two-phase: single-dose pharmacokinetics and 4-week supplementation with resistance training. (Nutrients)
30 healthy adults stratified by age. Crossover with 4-week washout.
Single-dose AstraGin® increased AUC by 6.67% for valine, 3.62% for leucine, 0.15% for isoleucine vs placebo. After 4 weeks, AstraGin® continued to enhance amino acid absorption and supported arginine uptake. Effects most pronounced in older adults (60-80). Functional improvements: increased grip strength and muscle mass in elderly group. Industry-funded (NuLiv Science) — independent replication needed.
NuLiv Science-published human clinical trial of AstraGin® (50 mg/day) effects on gut microbiome composition, intestinal barrier function (zonulin), and inflammatory markers. Note: full peer-reviewed details not currently indexed in PubMed under this trial branding; also reported zonulin improvements.
30 healthy adults stratified into three age groups (18-25, 26-59, 60-80 years; n=10 each). Randomized, double-blind, placebo-controlled crossover trial; 50 mg AstraGin® or placebo + 25 g whey protein. Two phases: (1) acute single-dose PK with 8-point amino acid measurements 0-180 min; (2) 4-week home-based supplementation + resistance training. NCT06110260.
After 4 weeks, AstraGin® significantly increased valine AUC by 14.07%, leucine by 8.34%, and improved isoleucine by 6.33% vs placebo. Older adults (60-80) showed 12.74% greater total essential amino acid AUC increase. Grip strength improved more with AstraGin® (+5.20%) vs placebo (+2.44%); muscle mass +0.85% vs +0.68%. Blood zonulin reduced 13.01% (intestinal barrier improvement) vs 0.90% in placebo. No adverse effects. First peer-reviewed human trial directly testing AstraGin® on whey protein PK and muscle function.